MEDI-528, now recognized as enokizumab , represents a innovative therapeutic targeting the IGF-1R , a key protein linked in several epidermal conditions . Early trial results suggest considerable potential for the lessening of significant atopic dermatitis , particularly in patients who have responded poorly to existing therapies . This antibody de